Aspirin May Boost Breast Cancer Survival, But Clinical Trials Are Needed


The original maker of aspirin, Bayer AG, probably couldn't be happier: Its so-called wonder drug is already famously touted as helping to lower the risk of heart attacks and strokes, and the list of diseases and disorders that it and other nonsteroidal anti-inflammatory drugs (NSAIDs) combat continues to grow. Now, a new study published in the Journal of Clinical Oncology says we can add another benefit to aspirin's resume: breast cancer survival.